NeuClone Pharmaceuticals discloses potential biosimilar pembrolizumab

Sep 1, 2020

NeuClone Pharmaceuticals discloses it is working on a biosimilar referencing Keytruda® (pembrolizumab). The product is in the advanced stages of pre-clinical development and is being developed in partnership with the Serum Institute of India.

Print Page Mail Article